Cryotherapy + Imiquimod Active in Cutaneous Metastases of Melanoma

This article originally appeared here.
Cryotherapy + Imiquimod Active in Cutaneous Melanoma Mets
Cryotherapy + Imiquimod Active in Cutaneous Melanoma Mets

HealthDay News — Cryotherapy combined with topical imiquimod 5% is an active treatment for locoregional cutaneous metastases of melanoma (LCMM), according to research published online Dec. 12 in the Journal of Dermatology.

Noting that treatment of LCMM represents a therapeutic challenge, Nancy Rivas-Tolosa, MD, from the Instituto Valenciano de Oncología in Valencia, Spain, and colleagues evaluated the efficacy of the combination of cryotherapy and topical imiquimod 5% for treating the disease. The authors documented the locoregional cutaneous response to the treatment in 20 patients diagnosed with LCMM.

The researchers found that 65% of patients responded to treatment after a mean of five sessions: 40% with complete response and 25% with partial response. In 80% of patients, systemic disease progressed.

"Cryotherapy followed by topical imiquimod 5% is simple to apply, has minimal adverse effects, and provides response rates similar to other, more complex treatment options," the authors write.

Full Text (subscription or payment may be required)